FAB Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - Fusion Antibodies PLC - Alpha Spread

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 3.3 GBX Market Closed
Market Cap: 3.1m GBX
Have any thoughts about
Fusion Antibodies PLC?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Fusion Antibodies PLC

Revenue
1.6m GBP
Cost of Revenue
-1.7m GBP
Gross Profit
-117k GBP
Operating Expenses
-2.9m GBP
Operating Income
-3m GBP
Other Expenses
184k GBP
Net Income
-2.8m GBP

Margins Comparison
Fusion Antibodies PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
Fusion Antibodies PLC
LSE:FAB
3.1m GBP
-7%
-191%
-180%
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
55%
14%
6%
US
Thermo Fisher Scientific Inc
NYSE:TMO
233.5B USD
41%
18%
15%
US
Danaher Corp
NYSE:DHR
192.7B USD
59%
21%
19%
KR
Samsung Biologics Co Ltd
KRX:207940
68.7T KRW
50%
31%
24%
CH
Lonza Group AG
SIX:LONN
38.7B CHF
29%
13%
9%
US
IQVIA Holdings Inc
NYSE:IQV
44.3B USD
35%
14%
9%
US
Agilent Technologies Inc
NYSE:A
39.4B USD
55%
25%
22%
US
Mettler-Toledo International Inc
NYSE:MTD
29.2B USD
59%
28%
21%
IE
ICON PLC
NASDAQ:ICLR
25.1B USD
30%
14%
9%
US
West Pharmaceutical Services Inc
NYSE:WST
21.6B USD
36%
21%
18%
Country UK
Market Cap 3.1m GBP
Gross Margin
-7%
Operating Margin
-191%
Net Margin
-180%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Operating Margin
14%
Net Margin
6%
Country US
Market Cap 233.5B USD
Gross Margin
41%
Operating Margin
18%
Net Margin
15%
Country US
Market Cap 192.7B USD
Gross Margin
59%
Operating Margin
21%
Net Margin
19%
Country KR
Market Cap 68.7T KRW
Gross Margin
50%
Operating Margin
31%
Net Margin
24%
Country CH
Market Cap 38.7B CHF
Gross Margin
29%
Operating Margin
13%
Net Margin
9%
Country US
Market Cap 44.3B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 39.4B USD
Gross Margin
55%
Operating Margin
25%
Net Margin
22%
Country US
Market Cap 29.2B USD
Gross Margin
59%
Operating Margin
28%
Net Margin
21%
Country IE
Market Cap 25.1B USD
Gross Margin
30%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 21.6B USD
Gross Margin
36%
Operating Margin
21%
Net Margin
18%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Fusion Antibodies PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
Fusion Antibodies PLC
LSE:FAB
3.1m GBP
-141%
-94%
-139%
-206%
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
2%
1%
3%
3%
US
Thermo Fisher Scientific Inc
NYSE:TMO
233.5B USD
14%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
192.7B USD
8%
5%
6%
5%
KR
Samsung Biologics Co Ltd
KRX:207940
68.7T KRW
10%
6%
11%
7%
CH
Lonza Group AG
SIX:LONN
38.7B CHF
6%
3%
6%
5%
US
IQVIA Holdings Inc
NYSE:IQV
44.3B USD
23%
5%
11%
9%
US
Agilent Technologies Inc
NYSE:A
39.4B USD
25%
13%
18%
17%
US
Mettler-Toledo International Inc
NYSE:MTD
29.2B USD
-648%
24%
49%
29%
IE
ICON PLC
NASDAQ:ICLR
25.1B USD
8%
4%
8%
6%
US
West Pharmaceutical Services Inc
NYSE:WST
21.6B USD
20%
15%
20%
18%
Country UK
Market Cap 3.1m GBP
ROE
-141%
ROA
-94%
ROCE
-139%
ROIC
-206%
Country US
Market Cap 1.3T USD
ROE
2%
ROA
1%
ROCE
3%
ROIC
3%
Country US
Market Cap 233.5B USD
ROE
14%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 192.7B USD
ROE
8%
ROA
5%
ROCE
6%
ROIC
5%
Country KR
Market Cap 68.7T KRW
ROE
10%
ROA
6%
ROCE
11%
ROIC
7%
Country CH
Market Cap 38.7B CHF
ROE
6%
ROA
3%
ROCE
6%
ROIC
5%
Country US
Market Cap 44.3B USD
ROE
23%
ROA
5%
ROCE
11%
ROIC
9%
Country US
Market Cap 39.4B USD
ROE
25%
ROA
13%
ROCE
18%
ROIC
17%
Country US
Market Cap 29.2B USD
ROE
-648%
ROA
24%
ROCE
49%
ROIC
29%
Country IE
Market Cap 25.1B USD
ROE
8%
ROA
4%
ROCE
8%
ROIC
6%
Country US
Market Cap 21.6B USD
ROE
20%
ROA
15%
ROCE
20%
ROIC
18%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top